Natural Killer Cells Therapies- Competitive Landscape,Technology and Pipeline Analysis, 2017

Publisher Name :
Date: 01-Apr-2017
No. of pages: 207
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's report, "Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, 2017", emphasizes on the currently active NK cell therapy products and NK cell augmenters in research and development.

The report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell based therapies and drugs that augment (enhance or activate) the NK cells. The report provides in-depth analysis on the Natural Killer Cell based therapies profiles along with the augmenting therapies covering their pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens. The report provides the NK Cell based therapies licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis.

Reports Highlights:

NK cell Therapy Pipeline scenario which includes NK cell therapies and NK cell augmenting therapies.

Collaborations & partnering deals

Current Prominent Research Areas and Key Players

Pipeline product profiles NK Cell therapy Technologies and NK cell Augmenting Therapies

Licensing opportunities

Market Drivers and Barriers

Scope

Overview of the global NK cell therapy and NK cell augmenting therapies pipeline scenario, products and associated companies information

Coverage of global NK cell therapies and drugs that enhance the activity of NK under development

Competitive landscape of products for key players and related indications

Coverage of licensors, collaborators and development partners, deal terms and deal values estimation

Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities

Highlights of licensing & collaboration opportunities and funding details

Highlights of latest NK cell therapy technologies and NK cell augmenting therapies and innovative companies

Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis

Natural Killer Cells Therapies- Competitive Landscape,Technology and Pipeline Analysis, 2017

Table of Contents

Report Introduction 1
Reports Highlights 1
Scope 1
Executive Summary 12
Natural Killer Cells Therapy Overview 13
Leading Companies with NEXT Generation Technologies 16
Market Drivers 17
Market Barriers 19
SWOT Analysis 20
Natural Killer Cells Based Therapies 21
Natural Killer Cells Based Therapies and Targets 22
NK Cells Based Therapy Collaborations 24
Collaborations and Deal Year 24
Collaborations and Deal value 24
Licensing Agreement for Future Developments 25
Institutes involved in NK cells based therapies 26
NK Cells Based Therapies and Technologies 28
Clinical trials & Completion Year 30
Phase II Trials 30
Phase I Trials 31
Pipeline Therapeutics for Natural Killer Cells Based Therapies 32
Therapeutics under Development by Companies 33
Mid Stage Products (Phase II) 34
Comparative Analysis 34
Early Stage Products (Phase I and IND) 47
Comparative Analysis 47
Pre-Clinical Products 58
Comparative Analysis 58
Therapeutic Assessment of Natural Killer Cell Therapies 99
Assessment by Monotherapy Products 99
Assessment by Combination Products 100
Assessment by Route of Administration 101
Assessment by Stage and Route of Administration 102
Assessment by Molecule Type 103
Assessment by Stage and Molecule Type 104
Assessment by Domain 105
Assessment by Stage and Domain 106
Natural Killer Cell Augmenters 107
Targets of Natural Killer Cells Augmenters and Their Analysis 108
NK Cells Augmenters Based Therapy Collaborations
Collaborations and Deal Year 109
Collaborations and Deal value 110
Licensing Agreement for future development of NK Cell Augmenters Therapy 111
Financing details of NK cells augmenters based therapies 113
Companies received Grants for NK cells augmenters based therapies
Designation
Institutes involved in NK Cells Augmenters Based Therapies
NK Cells Augmenters Based Therapies and Technologies
Clinical trials & Completion Year
Phase III Trials
Phase II Trials
Phase I Trials
Pipeline Therapeutics for Natural Killer Cells Augmenters(Enhancers & Activators)
Therapeutics under Development by Companies
NK Cells Enhancers
NK Cells Activators
Natural Killer Cell Enhancers
Late Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre -clinical Products
Comparative Analysis
Natural Killer Cells Activators
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre -clinical Products
Comparative Analysis
Therapeutic Assessment of Natural Killer Cell Augmenters (Enhancers & Activators)
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Domain
Assessment by Stage and Domain
Appendix
Report Methodology
DelveInsight Consulting Services
About DelveInsight
Contact Us
Disclaimer



List of Tables

Table 1:SWOT analysis of NK Cells Based Therapies& Augmenters, 2017
Table 2: Targets and Number of Products
Table 3:Natural Killer Cells based therapies -Target Antigens and Companies
Table 4:Collaboration and Deal Values for NK cell therapy, 2017
Table 5:Licensing Agreement for future development of NK Cell based Therapies, 2017
Table 6: Institute involved in NK Cells based Therapies, 2017
Table 7 : Companies and their technologies for NK Cells Based Therapies, 2017
Table 8: Natural Killer Cell based therapies-Study Completion Date of Phase II Drugs, 2017
Table 9: Natural Killer Cell based therapies-Study Completion Date of Phase I Drugs, 2017
Table 10:Number of Products Under Development for Natural Killer Cells Therapies, 2017
Table 11: Number of Products under development by Companies, 2017
Table 12: Mid Stage Products (Phase II), 2017
Table 13: Early Stage Products (Phase I), 2017
Table 14: Pre-Clinical Products, 2017
Table 15: Assessment by Monotherapy Products, 2017
Table 16:Assessment by Combination Products, 2017
Table 17: Assessment by Route Of Administration, 2017
Table 18:Assessment by Stage and Route Of Administration, 2017
Table 19: Assessment by Molecule Type, 2017
Table 20: Assessment by Stage and Molecule Type, 2017
Table 21:Assessment by Stage of development and Domain, 2017
Table 22:Assessmentby Stage of development and Domain, 2017
Table 23:Targets and Number of Products
Table 24:Natural Killer Cells Augmenters based therapies -Target Antigens and Companies
Table 25:Collaboration and Deal Values for NK cell Augmenters therapy, 2017
Table 26: Licensing Agreement for future development of NK Cell Augmenters Therapy, 2017
Table 27:Companies of NK cells augmenters based therapies financing for future developments, 2017
Table 28:Companies of NK cells Augmenters Received Grants, 2017
Table 29: Analysis of Natural Killer Cells Augmenters On The Basis of Designation, 2017
Table 30: Institute involved in NK Cells Augmenters, 2017
Table 32: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase III Drugs, 2017
Table 33: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase II Drugs, 2017
Table 34: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase I Drugs, 2017
Table 35:Number of Products Under Development for Natural Killer Cells Augmenters(Enhancers & Activators), 2017
Table 36: Number of Products under development by Companies, 2017
Table 37: Number of Products under development by Companies, 2017
Table 38: Late Stage Products (Phase III), 2017
Table 39: Mid Stage Products (Phase II), 2017
Table 40: Early Stage Products (Phase I), 2017
Table 41: Pre -clinical Products (Phase I), 2017
Table 42: Mid Stage Products (Phase II), 2017
Table 43: Early Stage Products (Phase I), 2017
Table 44: Pre -clinical Products (Phase I), 2017
Table 45: Assessment by Monotherapy Products, 2017
Table 46: Assessment by Route Of Administration, 2017
Table 47:Assessment by Stage and Route Of Administration, 2017 200
Table 48: Assessment by Molecule Type, 2017
Table 49: Assessment by Stage and Molecule Type, 2017
Table 50:Assessment by Stage of development and Domain, 2017
Table 51:Assessmentby Stage of development and Domain, 2017



List of Figures

Figure 1: Mechanism of action
Figure 2:NK Cells Therapy Collaborations and Deal Year, 2014-2016
Figure 3:Natural Killer Cell based therapies-Study Completion Date of Phase II Drugs, 2017
Figure 4:Natural Killer Cell based therapies-Study Completion Date of Phase I Drugs, 2017
Figure 5:Number of Products under Development for Natural Killer Cells Therapies,2017
Figure 6: Mid Stage Products (Phase II), 2017
Figure 7:Early Stage Products (Phase I), 2017
Figure 8:Pre-Clinical Products, 2017
Figure 9: Assessment by Monotherapy Products,2017
Figure 10: Assessment by Combination Products, 2017
Figure 11: Assessment by Route of Administration, 2017
Figure 12: Assessment by Stage and Route of Administration,2017
Figure 13: Assessment by Molecule Type,2017
Figure 14: Assessment by Stage and Molecule Type,2017
Figure 15: Assessment by Domain, 2017
Figure 16:Assessmentby Stage and Domain, 2017
Figure 17:NK Cells Augmenters Based Therapy Collaborations and Deal Year, 2017
Figure 18:NK Cells Augmenters based therapies designation and Number of Products, 2017
Figure 19:Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase III Drugs, 2017
Figure 20:Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase II Drugs, 2017
Figure 21:Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase I Drugs, 2017
Figure 23:Late Stage Products (Phase III), 2017
Figure 24: Mid Stage Products (Phase II), 2017
Figure 25:Early Stage Products (Phase I), 2017
Figure 26:Pre -clinical Products (Phase I), 2017
Figure 27: Mid Stage Products (Phase II), 2017
Figure 28:Early Stage Products (Phase I), 2017
Figure 29:Pre -clinical Products (Phase I), 2017
Figure 30: Assessment by Monotherapy Products,2017
Figure 31: Assessment by Route of Administration, 2017
Figure 32: Assessment by Stage and Route of Administration,2017
Figure 33: Assessment by Molecule Type,2017
Figure 34: Assessment by Stage and Molecule Type,2017
Figure 35: Assessment by Domain, 2017
Figure 36:Assessmentby Stage and Domain, 2017

  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 35
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and som......
  • Behcet Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 65
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2017, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, h......
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 64
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2017, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headach......
  • Post Menopausal Osteoporosis - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 73
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2017, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone stru......
  • Pompe Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pompe Disease - Pipeline Review, H1 2017, provides an overview of the Pompe Disease (Metabolic Disorders) pipeline landscape.Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). This enzyme is needed to break down glycogen, a form of sugar stored in muscle cells. When too much glycogen builds up ......
  • Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wri......
  • LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2017
    Published: 12-May-2017        Price: US 1250 Onwards        Pages: 57
    DelveInsight's, "LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. This report provides information on the therapeutic development based on the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists dealing with all the pipeline......
  • Radiation Toxicity - Pipeline Review, H1 2017
    Published: 09-May-2017        Price: US 2000 Onwards        Pages: 202
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal ......
  • Guillain-Barre Syndrome - Pipeline Review, H1 2017
    Published: 09-May-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2017, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrica......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs